Charles River To Perform Plasmid Production For Ship Of Theseus
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories International, Inc. (NYSE:CRL) has entered into a GMP plasmid DNA contract development and manufacturing organization (CDMO) agreement with Ship of Theseus to produce GMP grade plasmid DNA for therapeutic use. This collaboration aims to support the development of therapies for a wide range of conditions including diabetic and chronic wounds, neutropenia, psoriasis, androgenetic alopecia, women's health and infertility, and epithelial cancers. The production will be led by Charles River's center of excellence in Keele, United Kingdom.
April 04, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories partners with Ship of Theseus for the production of GMP grade plasmid DNA, targeting a broad range of therapeutic applications.
The partnership with Ship of Theseus positions Charles River Laboratories at the forefront of therapeutic development for a variety of conditions, potentially boosting its market position and revenue through the provision of specialized manufacturing services. The broad range of target indications suggests a significant market opportunity, likely leading to a positive short-term impact on CRL's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90